These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 2137367)

  • 1. Preliminary study of the treatment of advanced breast cancer in postmenopausal women with the aromatase inhibitor CGS 16949A.
    Stein RC; Dowsett M; Davenport J; Hedley A; Ford HT; Gazet JC; Coombes RC
    Cancer Res; 1990 Mar; 50(5):1381-4. PubMed ID: 2137367
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Specificity of low dose fadrozole hydrochloride (CGS 16949A) as an aromatase inhibitor.
    Santen RJ; Demers LM; Lynch J; Harvey H; Lipton A; Mulagha M; Hanagan J; Garber JE; Henderson IC; Navari RM
    J Clin Endocrinol Metab; 1991 Jul; 73(1):99-106. PubMed ID: 1646219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I trial of CGS 16949A. A new aromatase inhibitor.
    Lipton A; Harvey HA; Demers LM; Hanagan JR; Mulagha MT; Kochak GM; Fitzsimmons S; Sanders SI; Santen RJ
    Cancer; 1990 Mar; 65(6):1279-85. PubMed ID: 2137721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II study of vorozole (R83842), a new aromatase inhibitor, in postmenopausal women with advanced breast cancer in progression on tamoxifen.
    Goss PE; Clark RM; Ambus U; Weizel HA; Wadden NA; Crump M; Walde D; Tye LM; De Coster R; Bruynseels J
    Clin Cancer Res; 1995 Mar; 1(3):287-94. PubMed ID: 9815984
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of aromatase with CGS 16949A in postmenopausal women.
    Santen RJ; Demers LM; Adlercreutz H; Harvey H; Santner S; Sanders S; Lipton A
    J Clin Endocrinol Metab; 1989 Jan; 68(1):99-106. PubMed ID: 2521224
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potency and selectivity of the non-steroidal aromatase inhibitor CGS 16949A in postmenopausal breast cancer patients.
    Dowsett M; Stein RC; Mehta A; Coombes RC
    Clin Endocrinol (Oxf); 1990 May; 32(5):623-34. PubMed ID: 2142026
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor effects of a nonsteroidal aromatase inhibitor (CGS 16949A) on 7, 12-dimethylbenz[alpha]anthracene-induced mammary tumors in rats.
    Iino Y; Sugamata N; Owada S; Tago T; Sato H; Yokoe T; Maemura M; Morishita Y; Horiuchi R
    Jpn J Clin Oncol; 1991 Jun; 21(3):153-9. PubMed ID: 1834875
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CGS 16949A, a new nonsteroidal aromatase inhibitor: effects on hormone-dependent and -independent tumors in vivo.
    Schieweck K; Bhatnagar AS; Matter A
    Cancer Res; 1988 Feb; 48(4):834-8. PubMed ID: 2962734
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I study of the oral nonsteroidal aromatase inhibitor CGS 20267 in postmenopausal patients with advanced breast cancer.
    Iveson TJ; Smith IE; Ahern J; Smithers DA; Trunet PF; Dowsett M
    Cancer Res; 1993 Jan; 53(2):266-70. PubMed ID: 8417819
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiproliferative effect of the new aromatase inhibitor fadrozole on pre- and postmenopausal models of rat mammary tumor.
    Tanaka M; Yano S; Hasegawa Y; Nakao K
    Arzneimittelforschung; 1994 Jun; 44(6):774-8. PubMed ID: 8053980
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of CGS 16949A, an aromatase inhibitor on adrenal mineralocorticoid biosynthesis.
    Demers LM; Melby JC; Wilson TE; Lipton A; Harvey HA; Santen RJ
    J Clin Endocrinol Metab; 1990 Apr; 70(4):1162-6. PubMed ID: 2156889
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A study of fadrozole, a new aromatase inhibitor, in postmenopausal women with advanced metastatic breast cancer.
    Raats JI; Falkson G; Falkson HC
    J Clin Oncol; 1992 Jan; 10(1):111-6. PubMed ID: 1530798
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fadrozole hydrochloride in postmenopausal patients with metastatic breast carcinoma.
    Miller AA; Lipton A; Henderson IC; Navari R; Mulagha MT; Cooper J
    Cancer; 1996 Aug; 78(4):789-93. PubMed ID: 8756373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Approval summary: letrozole in the treatment of postmenopausal women with advanced breast cancer.
    Cohen MH; Johnson JR; Li N; Chen G; Pazdur R
    Clin Cancer Res; 2002 Mar; 8(3):665-9. PubMed ID: 11895893
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CGS 16949A, a new aromatase inhibitor in the treatment of breast cancer--a phase I study.
    Beretta KR; Hoeffken K; Kvinnsland S; Trunet P; Chaudri HA; Bhatnagar AS; Goldhirsch A; Cavalli F
    Ann Oncol; 1990 Nov; 1(6):421-6. PubMed ID: 2150591
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and endocrine effects of the oral aromatase inhibitor vorozole in postmenopausal patients with advanced breast cancer.
    Johnston SR; Smith IE; Doody D; Jacobs S; Robertshaw H; Dowsett M
    Cancer Res; 1994 Nov; 54(22):5875-81. PubMed ID: 7954417
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The new aromatase inhibitor CGS-16949A suppresses aldosterone and cortisol production by human adrenal cells in vitro.
    Lamberts SW; Bruining HA; Marzouk H; Zuiderwijk J; Uitterlinden P; Blijd JJ; Hackeng WH; De Jong FH
    J Clin Endocrinol Metab; 1989 Oct; 69(4):896-901. PubMed ID: 2550511
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Phase I study of CGS16949A--a new aromatase inhibitor. Cooperative Study Group for CGS16949A].
    Nomura Y; Abe O; Tominaga T; Tashiro H; Hisamatsu K; Enomoto K; Fujiwara K; Imoto S; Ando J; Hayashi K
    Gan To Kagaku Ryoho; 1994 Feb; 21(2):189-97. PubMed ID: 8311489
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Premenopausal breast cancer patients treated with a gonadotropin-releasing hormone analog alone or in combination with an aromatase inhibitor: a comparative endocrine study.
    Celio L; Martinetti A; Ferrari L; Buzzoni R; Mariani L; Miceli R; Seregni E; Procopio G; Cassata A; Bombardieri E; Bajetta E
    Anticancer Res; 1999; 19(3B):2261-8. PubMed ID: 10472341
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fadrozole HCL (CGS-16949A) versus megestrol acetate treatment of postmenopausal patients with metastatic breast carcinoma: results of two randomized double blind controlled multiinstitutional trials.
    Buzdar AU; Smith R; Vogel C; Bonomi P; Keller AM; Favis G; Mulagha M; Cooper J
    Cancer; 1996 Jun; 77(12):2503-13. PubMed ID: 8640699
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.